Back to top
more

IDEXX Laboratories (IDXX)

(Real Time Quote from BATS)

$627.34 USD

627.34
469,786

-14.60 (-2.27%)

Updated Aug 6, 2025 02:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

TransMedics (TMDX) Receives FDA Nod for OCS Heart System

by Zacks Equity Research

TransMedics' (TMDX) OCS Heart System is expected to enable broader use of donor hearts for transplantation in the United States.

Zacks Equity Research

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) owing to strong segmental performance and strategic buyouts and collaborations.

Zacks Equity Research

Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure

by Zacks Equity Research

Insulet (PODD) is gradually improving with respect to seamless supply chain and manufacturing operations.

Zacks Equity Research

Masimo's (MASI) ORi Favored by New Study For ICU Patients' ETI

by Zacks Equity Research

Masimo's (MASI) ORi is expected to provide early warnings of impending hypoxemia during the ETI procedure, thus aiding in averting any adverse incident.

Zacks Equity Research

Omnicell (OMCL) Opens New Software Development Center in India

by Zacks Equity Research

Omnicell's (OMCL) new software development center in Bangalore, India, is expected to bolster the company's cloud-based solutions portfolio.

Zacks Equity Research

Baxter (BAX) to Benefit From Hill-Rom Buyout: Here's How

by Zacks Equity Research

Baxter's (BAX) latest acquisition is likely to accelerate its digitally-enabled connected care solutions across the care continuum and enhance patient services.

Zacks Equity Research

Here's Why You Should Add STERIS (STE) to Your Portfolio Now

by Zacks Equity Research

STERIS (STE) ended first-quarter fiscal 2022 with better-than-expected results and strong segmental performance, driving the top line.

Zacks Equity Research

Zimmer Biomet (ZBH) Hurt by EMEA's Slow Recovery Amid Pandemic

by Zacks Equity Research

Zimmer Biomet's (ZBH) leveraged capital structure is an added concern.

Zacks Equity Research

Quidel's (QDEL) QuickVue OTC COVID-19 Test Now Widely Available

by Zacks Equity Research

In-store and online availability of Quidel's (QDEL) QuickVue OTC COVID-19 Test is expected to meet the rising COVID-19 testing needs across the United States.

Zacks Equity Research

Thermo Fisher (TMO) Gains Government Contract for Pipette Tip

by Zacks Equity Research

Thermo Fisher (TMO) will co-invest with the U.S. government to build a new manufacturing center for pipette tips in North Carolina.

Sapna Bagaria headshot

Hold Petco (WOOF) as It Rides on Continued Demand for Pet Care

by Sapna Bagaria

Petco (WOOF) by dint of its wide product and services portfolio, omni-channel presence and strategic initiatives is well poised to cash in on the expanding petcare industry.

Zacks Equity Research

AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?

by Zacks Equity Research

Investors are optimistic about AMN Healthcare's (AMN) broad array of services.

Zacks Equity Research

Veeva (VEEV) MedTech Suite to Aid B. Braun Speed Up Trials

by Zacks Equity Research

Adoption of Veeva's (VEEV) unified suites of cloud applications is likely to provide a significant boost to the company's Veeva Development Cloud business.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Varex Imaging, Omnicell, STAAR Surgical and IDEXX Laboratories

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Varex Imaging, Omnicell, STAAR Surgical and IDEXX Laboratories

Zacks Equity Research

BD's (BDX) Latest Diagnostic System to Improve Lab Efficiency

by Zacks Equity Research

BD's (BDX) new system is expected to address labs' needs for high-volume processing and increases in efficiency.

Urmimala Biswas headshot

4 MedTechs to Gain in 2H21 Beating the Delta Variant-Led Dip

by Urmimala Biswas

Investors can choose to invest in MedTech stocks like VREX, OMCL, STAA, and IDXX that have shown tremendous promise amid the pandemic.

Zacks Equity Research

Stock Market News for Aug 31, 2021

by Zacks Equity Research

The S&P 500 and the Nasdaq closed at record highs on Monday as investors flocked to technology and consumer discretionary shares, after the Federal Reserve¿¿¿s dovish stance on tapering its monetary stimulus last week.

Zacks Equity Research

Should JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JPME

Zacks Equity Research

Idexx (IDXX) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Idexx (IDXX) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Reasons to Hold on to Veeva Systems (VEEV) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.

Zacks Equity Research

Here's Why You Should Retain Integra (IART) Stock for Now

by Zacks Equity Research

Solid performance across the CSS and Tissue Technologies segments is driving the top line for Integra (IART).

Zacks Equity Research

Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for TIBSOVO

by Zacks Equity Research

Thermo Fisher (TMO) receives FDA go-ahead for the Oncomine Dx Target Test as a CDx for Servier's ivosidenib tablets, TIBSOVO.

Zacks Equity Research

SmileDirectClub (SDC) Reels Under Rising Costs, Debt Woes

by Zacks Equity Research

SmileDirectClub (SDC) sees net operating cash outflow in the second quarter.

Zacks Equity Research

BD (BDX) Veritor At-Home COVID-19 Test Receives EUA From FDA

by Zacks Equity Research

EUA for BD's (BDX) At-Home COVID-19 test is expected to boost home testing to prevent outbreaks and limit the rise in COVID-19 cases from the Delta variant.

Zacks Equity Research

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and regulatory approvals.